Compare CVS Health Corp (CVS) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs State Street Technology Select Sector SPDR ETF — how do they compare? CVS Health Corp trades at $94.83 (market cap $119.58B), while State Street Technology Select Sector SPDR ETF trades at $189.2. The key difference: CVS Health Corp pays a 2.84% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | XLK | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Sector/Thematic |
52-Week High | $110.60 | $198.21 |
52-Week Low | $65.51 | $127.49 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.
CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.
XLK trades at $189.38, up 1.64% with strong technical momentum as moving averages signal bullish conditions. The Technology Select Sector SPDR Fund shows institutional interest with record sector ETF inflows of $25 billion in July 2026 (ETF Trends, 2026-08-10). Recent earnings strength from holdings like Microsoft supports the fund's performance, though RSI levels suggest potential near-term overbought conditions.
Outlook remains positive given sector earnings growth and AI-driven momentum, but risks include concentration in mega-cap stocks and valuation concerns. The fund's heavy reliance on top holdings creates sensitivity to individual company performance, requiring careful monitoring of diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
